[
    [
        {
            "time": "",
            "original_text": "【光大金工|调整名单预测】凯莱英、紫光国微或纳入沪深300指数成分股",
            "features": {
                "keywords": [
                    "凯莱英",
                    "紫光国微",
                    "沪深300",
                    "成分股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "半导体"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【光大金工|调整名单预测】凯莱英、紫光国微或纳入沪深300指数成分股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "疫情影響逐漸消退，關注高成長龍頭+細分冠軍 -- 医藥生物上市公司2020年三季報小結",
            "features": {
                "keywords": [
                    "疫情",
                    "高成长",
                    "龙头",
                    "细分冠军",
                    "医药生物",
                    "三季报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "疫情影響逐漸消退，關注高成長龍頭+細分冠軍 -- 医藥生物上市公司2020年三季報小結",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "【浙商医药|三季报】創新藥研發高景氣有望持續，看好CDMO業績加速",
            "features": {
                "keywords": [
                    "创新药",
                    "研发",
                    "高景气",
                    "CDMO",
                    "业绩加速",
                    "三季报"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【浙商医药|三季报】創新藥研發高景氣有望持續，看好CDMO業績加速",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]